Quick Answer
AEON Biopharma, Inc. reported Cash and Equivalents of $3.01 million for fiscal year 2025.
AEON Biopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.01M | +23023.1% |
| 2024 | $13.0K | -99.7% |
| 2023 | $5.16M | -83.5% |
| 2023 | $31.20M | +220.1% |
| 2022 | $9.75M | +1859.3% |
| 2021 | $497.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.93M | +1003.7% | -29.8% |
| June 30, 2025 | $8.44M | +145.2% | -19.2% |
| March 31, 2025 | $10.45M | +570.5% | +80253.8% |
| December 31, 2024 | $13.0K | -99.7% | -97.6% |
| September 30, 2024 | $537.0K | -96.7% | -84.4% |
| June 30, 2024 | $3.44M | — | +120.9% |
| March 31, 2024 | $1.56M | — | -69.8% |
| December 31, 2023 | $5.16M | -47.1% | -68.1% |
- AEON Biopharma, Inc. showed an increase of +23023.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, AEON Biopharma, Inc.’s cash and equivalents has grown by 504.3% (from $497.4 thousand to $3.01 million).
- The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: